1	Risk of SARS-CoV-2 transmission by fomites: a clinical observational study in highly infectious			
2	COVID-19 patients			
3	Short title: Risk of SARS-CoV-2 transmission by fomites			
4				
5	Toni Luise Meister, M.Sc. <sup>1*</sup> , Marielen Dreismeier, M.D. <sup>2*</sup> , Elena Vidal Blanco <sup>1</sup> , Yannick			
6	Brüggemann, Dr. <sup>1</sup> , Natalie Heinen, M.Sc. <sup>1</sup> , Günter Kampf, Prof. <sup>3</sup> , Daniel Todt, Dr. <sup>1,4</sup> , Huu Phuc			
7	Nguyen, Prof <sup>5</sup> , Jörg Steinmann, Prof. <sup>6</sup> , Wolfgang Ekkehard Schmidt, Prof. <sup>2</sup> , Eike Steinmann, Prof. <sup>1</sup> ,			
8	Daniel Robert Quast, Dr. <sup>2#</sup> and Stephanie Pfaender, Prof. <sup>1#</sup>			
9				
10	<sup>1</sup> Department for Molecular & Medical Virology, Ruhr-University Bochum, 44801 Bochum, Germany			
11	<sup>2</sup> Department of Medicine I, St. Josef-Hospital Bochum, Ruhr-University Bochum, 44791 Bochum,			
12	Germany			
13	<sup>3</sup> Institute for Hygiene and Environmental Medicine, University Medicine Greifswald, 17475			
14	Greifswald, Germany			
15	<sup>4</sup> European Virus Bioinformatics Center (EVBC), 07743 Jena, Germany			
16	<sup>5</sup> Department of Human Genetics, Ruhr-University Bochum, 44791 Bochum, Germany			
17	<sup>6</sup> Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University			
18	Nuremberg, Germany			
19				
20	* These authors contributed equally and share first authorship.			
21	<sup>#</sup> These authors contributed equally and share last authorship.			
22				
23	Funding: None.			
24	Word count: Abstract: 227; Text: 3049			
25	Corresponding author:			
26	JrProf. Dr. Stephanie Pfänder			
27	Department for Molecular & Medical Virology, Ruhr-University Bochum, 44801 Bochum, Germany			
28 20	Phone: $+49\ 234\ 32 - 29278$			
29	E-Man: stephane.prænder@runr-uni-bocnum.de			

30	Abstract				
31	Background:				
32	The contribution of droplet-contaminated surfaces for virus transmission has been discussed				
33	controversially in the context of the current Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-				
34	CoV-2) pandemic. Importantly, the risk of fomite-based transmission has not been systematically				
35	addressed.				
36	Methods:				
37	We initiated this single-center observational study to evaluate whether hospitalized COVID-19 patients				
38	can contaminate stainless steel carriers by coughing or intensive moistening with saliva and to assess				
39	the risk of SARS-CoV-2 transmission upon detection of viral loads and infectious virus in cell culture				
40	Fifteen hospitalized patients with a high baseline viral load (CT value $\leq 25$ ) shortly after admission were				
41	included. We documented clinical and laboratory parameters and used patient samples to perform viru				
42	culture, quantitative PCR and virus sequencing.				
43	Results:				
44	Nasopharyngeal and oropharyngeal swabs of all patients were positive for viral RNA on the day of the				
45	study. Infectious SARS-CoV-2 could be isolated from 6 patient swabs (46.2 %). While after coughing				
46	no infectious virus could be recovered, intensive moistening with saliva resulted in successful viral				
47	recovery from steel carriers of 5 patients (38.5 %).				
48	Conclusions:				
49	Transmission of infectious SARS-CoV-2 via fomites is possible upon extensive moistening, but unlikely				
50	to occur in real-life scenarios and from droplet-contaminated fomites.				
51					
52					
53					
54	Registration:	None.			
55	Keywords:	Coronavirus, SARS-CoV-2, COVID-19, fomites, surfaces, cough,			
56		transmission, environmental stability			

#### 57 Background

58 The emergence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the cause of the 59 Coronavirus Disease-19 (COVID-19), has raised the general awareness towards different hygiene and 60 prevention measures to limit viral spread. Although SARS-CoV-2 is mainly transmitted via respiratory 61 droplets and aerosols exhaled from infected individuals (e.g., upon breathing, speaking, coughing or 62 sneezing [1]), droplet-contaminated surfaces (fomites) have also been widely perceived as another 63 potential route of transmission. In particular, different studies reported that SARS-CoV-2 can persist on 64 inanimate surfaces for days under controlled laboratory conditions [2-4] and genomic material of 65 SARS-CoV-2 has been detected on diverse surfaces and materials in hospital, private and public settings 66 [5]. Consequently, a clinically significant risk of SARS-CoV-2 transmission by fomites has been 67 assumed and extensive hand hygiene and disinfection procedures have been initiated early during the 68 pandemic worldwide. Although recent studies suggest a low risk of viral transmission by fomites for 69 most instances [1,6], it is still considered possible given a timely order of events (e.g., direct 70 contamination of a surface by an infected individual followed by timely skin contact by another 71 individual and direct contact towards susceptible mucosae) [7]. However, most efforts to study surface 72 transmission of SARS-CoV-2 have either focused on the detection of viral RNA via RT-qPCR rather 73 than direct detection of infectious viral particles and/or employed lab-grown viruses which do not 74 recapitulate the specific infectivity of patient-derived SARS-CoV-2 particles. Consequently, these 75 findings do not necessarily allow to adequately estimate the potential of SARS-CoV-2 transmission 76 from directly contaminated surfaces.

To examine the risk of transmission by surfaces directly after contamination by individuals infected with SARS-CoV-2, we performed a clinical observational study, including hospitalized patients with high viral loads ( $CT \le 25$ , up to  $2.03 \times 10^9$  RNA copies). The aim of this study was to evaluate if confirmed hospitalized COVID-19 patients can contaminate stainless steel carriers by coughing or intensive moistening with saliva and to assess the risk of SARS-CoV-2 transmission upon detection of viral loads and infectious virus in cell culture.

#### 83 Methods

#### 84 *Study cohort.*

85 Hospitalized patients (age > 18 years) treated at St. Josef-Hospital Bochum, Germany, with confirmed 86 SARS-CoV-2 infection with a high virus load (RT-PCR from combined nasopharyngeal and 87 oropharyngeal swab (swab) with a cycle threshold (CT)  $\leq 25$  on admission) were included in this study. 88 The initial viral load was determined using Allplex<sup>™</sup> 2019-nCoV Assay (Seegene Inc., Seoul, Republic 89 of Korea) targeting three SARS-CoV-2 specific genes (E gene, RdRP gene and N gene) with a sensitivity 90 of 100 copies per run. Exclusion criteria were acute myocardial infarction, current need of ventilation 91 support systems (e.g., high flow- or non-invasive ventilation), current treatment in an intensive care unit, 92 evidence of drug or alcohol abuse, acute psychiatric disorders and any clinical or mental disorder that 93 might deteriorate the patient's condition during the standardized procedure of sampling (such as 94 dysphagia), as per investigator's judgement. Collected clinical data included medical history, current 95 daily medication, laboratory results, blood gas analysis, and results of x-rays or computed tomography 96 (to define the "clinical classification of COVID-19-infection" following the recommendation of the 97 World Health Organization (WHO) [8] and Robert Koch Institute (RKI) [9]).

98

99 Study design.

100 After written informed consent, two combined nasopharyngeal and oropharyngeal swabs were collected 101 from each patient. Then, patients were asked to forcefully cough two-times on a pre-defined surface 102 area containing nine standardized steel-carriers, each with a one-centimeter diameter ("cough"), using 103 a specially designed tripod with a defined distance of 15 centimeters (Appendix Figure 1). In addition, 104 patients were asked to moisten nine steel carriers with saliva for ten seconds within their mouth 105 ("moisten"). After defined time points at room temperature (1 min, 5 min, 15 min, 30 min, 45 min, 90 106 min, 120 min and 240 min), the steel-carriers were placed in containers containing 2 mL cold Dulbecco's 107 modified Eagle's medium (DMEM complete, supplemented with 10 % (v/v) fetal calf serum, 1 % non-108 essential amino acids, 100 IU/mL penicillin, 100 µg/mL streptomycin and 2 mM L-Glutamine) and 109 transported on ice to the biosafety level three laboratory of the Ruhr-University Bochum. The study was 110 conducted between November 2020 and April 2021.

111 Virus culture.

112 VeroE6 cells were seeded at  $3 \times 10^5$  cells/well in a six well cell culture plate and incubated for at least 113 four hours at 37 °C and 5 % CO<sub>2</sub>. Hereafter, the medium was replaced with 1.8 mL of patient swabs, 114 "cough" samples or "moisten" samples and 2.5  $\mu$ g/mL amphotericin B was added. Over a maximum 115 period of ten days, cells were monitored daily for the appearance of a cytopathic effect (CPE), indicating 116 productive virus infection. Upon visible CPE, cells were harvested for RT-qPCR and the supernatant 117 (SN) was collected for viral titration and RT-qPCR. Viral titers in the SN were quantified by endpoint-118 dilution and the 50 % tissue culture infective dose (TCID<sub>50</sub>/mL), calculated according to Spearman and 119 Kärber [10].

120

# 121 *Reverse Transcription Quantitative PCR (RT-qPCR).*

122 SARS-CoV-2 RNA was isolated from the supernatant using AVL buffer and the QIAamp Viral RNA 123 Kit (QIAGEN®, www.qiagen.com) according to the manufacturer's instructions. RNA was directly 124 subjected to one-step quantitative PCR (RT-qPCR) running a GoTaq Probe 1-Step RT-qPCR System 125 (Promega®, www.promega.com). Total RNA was purified from VeroE6 cells using the RNeasy Mini 126 Kit (OIAGEN®, www.giagen.com). Subsequently, 500 ng of total RNA were reverse transcribed using 127 the PrimeScript<sup>TM</sup> RT Master Mix (Takara®, www.takarabio.com) and subjected to two-step RT-qPCR 128 running a GoTaq Probe 2-Step RT-qPCR System (Promega®, www.promega.com). RT-qPCR was 129 performed as described previously [11] using a light cycler LC480 to quantify the M-Gene abundance.

130

131 Data analysis and sample size.

132 Clinical patient parameters are expressed as mean  $\pm$  SD or n (% of total). Results are expressed as means 133 ( $\pm$  SEM). Clinical characteristics were screened for correlations using Spearman's correlation 134 coefficient. Statistical significance was defined as  $\alpha$ =0.05. Statistical analysis was performed using 135 GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA, 136 www.graphpad.com). Sample size calculation was performed using G\*Power Version 3.1.9.6 for 137 windows [12].

139 *Legal and ethical considerations.* 

The study was conducted according to the revised principles of the Declaration of Helsinki and was
approved by the ethics committee of the Ruhr-University Bochum (registration number 20-7065) in
November 2020. All patients gave written informed consent.

143

144 Sequencing and strain assignment

145 RNA of the initial swaps was isolated using the NucleoSpin RNA kit (Macherey & Nagel) followed by 146 a reverse transcription utilizing the SuperScript IV together with Oligo dT and random hexamer primer 147 (Thermo Fisher) according to the manufacturers' instructions. Subsequently, the cDNA was subjected 148 to deep sequencing. Sequencing libraries were prepared from 4.5ul cDNA using NEBNext® ARTIC 149 SARS-CoV-2 Library Prep Kit for Illumina sequencing platforms (New England BioLabs® Inc., 150 neb.com, catalog #E7650). Concentration and size of the cDNA amplicons and libraries were assessed 151 using Qubit fluorometer and Tapestation (High Sensitivity D1000 ScreenTape), respectively. High 152 throughput paired end sequencing was performed using Illumina MiSeq sequencer and MiSeq Reagent 153 Kit v2 (500-cycles) following the manufacturer's recommendations. Raw reads were quality checked, 154 trimmed and mapped to the SARS-CoV-2 reference sequence (NCBI Reference Sequence: NC\_045512) 155 using QIAGEN CLC Genomics Workbench 21.0.5. After removing duplicates, partially full length 156 consensus sequences were extracted and samples were assigned to respective lineages using the pangolin 157 tool [13] (Table 2). In addition, variants in spike domains were identified and annotated using Geneious 158 prime 2021.2.2 (https://www.geneious.com).

#### 160 Results

161 *Study cohort.* 

162 A total of 15 patients (33.3 % female) between 39 and 89 years (mean age 70.5 ( $\pm$  12.5) years) were 163 recruited. Baseline parameters including laboratory findings on admission are presented in Table 1. All 164 study patients had risk factors for a severe course of COVID-19 according to the criteria of the WHO 165 [8] and RKI [14]. Three (20%) patients had up to two risk factors, while most patients had multiple risk 166 factors for a severe COVID-19 illness (3-4 risk factors: 7 (46.7 %), 5-6 risk factors: 2 (13.3 %), >6 risk 167 factors: 1 (6.7 %)). Body temperature on admission was  $37.0 (\pm -0.9)$  °C. On the study day, 9 (60 %) 168 patients were categorized with a mild COVID-19 disease according to STACOB criteria (adaptation 169 following the WHO Therapeutics and COVID-19:living guideline [8]). Nasal oxygen support was 170 required by seven (46.7 %) patients. Mean peripheral oxygen saturation on admission was 93.4 % (SEM 171  $\pm$  7.4 %). None of the included patients were vaccinated against SARS-CoV-2.

172 On the day of the study, most patients had only mild symptoms (n = 9/15, 60 %) and were categorized 173 to mild COVID-19 disease. Follow-up revealed a clinical worsening in 10 patients and 3 died (2 patients 174 died of COVID-19, 1 patient died with COVID-19). Consistent with literature [15], a high level of 175 lactate dehydrogenase (r=0.53, p=0.044), leucocytes (r=0.69, p=0.0056), but also C-reactive protein 176 (r=0.54, p=0.035) on admission was significantly correlated with a more severe COVID-19 infection 177 (Appendix Figure 2). No significant correlation was found for COVID-19 severeness and other 178 described severeness predictors including age (r=0.44, p=0.11), alanine aminotransferase (r=-0.31, 179 p=0.26), aspartate aminotransferase (r=0.07, p=0.81), procalcitonin (r=0.53, p=0.47), or D-dimers 180 (r=0.45, p=0.11).

- 181
- 182 SARS-CoV-2 viral load and sequencing.

The patients' viral load before sample acquisition as determined with the combined nasopharyngeal and oropharyngeal swabs are displayed in Table 2. Mean CT-values in RT-qPCR analyses were E-Gene  $15.3 (SEM \pm 2.7)$ , S-Gene  $18.1 (SEM \pm 4.9)$  RdRP-Gene  $17.2 (SEM \pm 3.7)$  and N-Gene  $19.4 (SEM \pm 5.5)$ . Viral variants included supposed wildtype (n=10, 66.7 %), variant of concern (VoC) Alpha (n=4,

187 26.7 %) and VoC Beta (n=1, 6.7 %). Deep sequencing using the pangolin tool [13] confirmed lineage

assignment for 14/15 (93·3 %) samples for nearly full-length genomes. Variant patterns identified by
detailed investigation of spike domains underlined lineage assignment according to RKI variant reports
[16] (Figure 1, Table 2).

191 Two patient samples were excluded from the study due to bacterial/fungal contamination within the 192 cultures (Appendix Table 1). Viral RNA could be detected from all (n=13/13) combined nasopharyngeal 193 and oropharyngeal swabs (inoculum) and viral RNA could be successfully detected within the 194 inoculated cell cultures (Figure 2, Appendix Figure 3). After inoculation with the "swabs", viral loads 195 in the cells ranged from  $2.23 \times 10^1$  to  $2.03 \times 10^9$  RNA copies/50 ng and in the supernatant from not 196 detectable to 6.58×10<sup>7</sup> RNA copies/mL (Appendix Table 1). Infectious virus ("Infectivity"), determined 197 as TCID<sub>50</sub>/mL, could be recovered from the nasal-oropharyngeal swabs from n=6/13 (46.2 %) patients 198 (Figure 2; P1, P2, P3, P5, P8, P10). Of note, despite inclusion criteria defining a high viral load (CT  $\leq$ 199 25, Table 2), some patients displayed lower viral loads at the time-point of the study, with none of the 200 swab samples resulting in productive virus infection in cell culture (Appendix Figure 3; P.11, P12, P13, 201 P14).

202

203 Evaluation of SARS-CoV-2 transmission risk.

204 Steel-carriers contaminated via intensive moistening with saliva (Figure 2, "moisten") resulted in a 205 visible CPE and detectable viral RNA within the cells (at least one time point positive) in n=6/13 (46.2 206 %) cases (P1, P2, P3, P5, P9, P10). Despite the absence of a visible CPE in patient 6 and patient 10 207 (Figure 2, time points 30 and 45 min), viral RNA was detected in the cells and supernatants, and 208 infectious virus was quantified, indicating that harvesting might have been too early for the appearance 209 of CPE. Infectious virus was recovered from n=5/13 (38.5 %) contaminated steel carriers (Figure 2; 210 "SN infectivity" P1, P3, P5, P6, P10) with viral titers ranging from  $5.59 \times 10^1$  to  $8.68 \times 10^5$  TCID<sub>50</sub>/mL. 211 In some patients, infectious virus could be recovered from the steel-carriers for up to 240 min after 212 incubation at room temperature (Figure 2; P1, P3, P5), underlining the environmental stability of SARS-213 CoV-2 over several hours. For other samples (Figure 2; P2, P6, P10), infectious virus could be recovered 214 at early time points only (1 min, 15 min, 30 min, 45 min).

After contamination with coughing, viral RNA could be weakly detected within five of the cellular samples (Figure 2; "cough" P1, P7, P8, P10, Appendix Figure 3; P11). However, none of the via coughing contaminated surfaces resulted in productive cellular infection as determined by the appearance of CPE and quantification of infectivity (Figure 2, Appendix Figure 3).

219

### 220 Discussion

221 While respiratory droplets and aerosols exhaled from infected individuals are currently considered the 222 main route of SARS-CoV-2 transmission, the role of droplet-contaminated surfaces (fomites) as a 223 potential source of infection remains controversial. Fomite-based transmission has been proposed to 224 contribute to the spread of other common respiratory pathogens [17,18], including experimental studies 225 examining the transfer of infectious influenza viruses and/or respiratory syncytial virus between hands 226 and surfaces [19]. However, current evidence points towards a low risk of SARS-CoV-2 transmission 227 in this scenario [1,20], requiring a timely order of specific events [7]. To examine this potential risk of 228 SARS-CoV-2 surface transmission, we assessed the amount of SARS-CoV-2 genomic material and 229 infectious viral particles after contamination by individuals infected with SARS-CoV-2 over time. The 230 results of the present study highlight that viral contamination via coughing on surfaces does not represent 231 a major risk of transmission.

232 Our study cohort was characterized by non-vaccinated, hospitalized, mostly elderly patients with 233 multiple comorbidities. Since the vaccination program in Germany started in December 2020 (during 234 the study period), none of the patients were vaccinated against SARS-CoV-2. This cohort may therefore 235 be quite representative for hospitalized patients during the first and second COVID-19 wave in most 236 countries [21]. However, since the proportion of unvaccinated people in the population remains 237 significant [22] and completely vaccinated individuals can still be infected and often present with high 238 viral loads [23], the present results remain of significant importance for the ongoing pandemic. Initially, 239 we were able to recruit patients in early stages of COVID-19 due to outbreaks in hospitals and 240 rehabilitation facilities and subsequently early referral to the isolation ward. Later, patients were 241 diagnosed in ambulatory settings and predominantly admitted via the emergency department, often only 242 when clinical conditions deteriorated and ambulatory management failed. The hospitalized cohort may explain the high rate of risk factors and, consequently, follow-up mortality in the present study.
However, the present cohort is characterized by high viral load. Hence, a high transmission rate can be
assumed [24], supporting the main conclusion of the study. Of note, several laboratory parameters on
admission significantly correlated with a severe outcome. However, the present study was not powered
for this analysis and therefore, these correlations need to be considered exploratory.

248 Infectious virus could be recovered from the combined nasopharyngeal and oropharyngeal swabs and 249 steel-carriers contaminated via intensive "moistening" from a significant number of patients. For some 250 patients, infectious virus could be recovered for up to 240 min (Figure 2). This demonstrates that 251 infectious virus can be transferred from saliva by moistening onto surfaces from patients and can be 252 recovered for several hours. As described previously, we did not observe differences of the viral stability 253 between the wildtype and VoCs (Alpha and Beta), implying a comparable environmental stability [25]. 254 The stability of SARS-CoV-2 on surfaces is likely determined by a combination of factors, including 255 the initial amount of infectious virus deposited, possible presence of antibodies within the sputum and 256 environmental parameters. Given the controlled laboratory conditions for virus recovery as herein 257 presented (e.g., large inoculums, small surface area, no UV exposure), the viral survival observed might 258 therefore differ from real-life scenarios, necessitating careful interpretation. For example, a recent study 259 observed a low transfer efficiency between different surfaces and fingertips following an initial drying of an inoculum with a low viral titer  $(1 \times 10^4 \text{ TCID}_{50}/\text{mL})$  [20]. Hence, even if sufficient viable virus is 260 261 deposited on a surface, a timely contact and high transfer efficiency are required to transfer an infectious 262 dose, which subsequently needs to be exposed towards susceptible tissues (e.g., mucosa, eyes). 263 Importantly, we did not observe the recovery of infectious virus after patients coughed onto a surface, 264 implying that droplet-contamination of surfaces does not present a major transmission route for SARS-265 CoV-2. Given that non-hospitalized and pre-symptomatic, asymptomatic, and mildly symptomatic 266 individuals across different age groups frequently display viral loads within a comparable range [26], 267 similar observations as herein observed for elderly and hospitalized patients can be inferred.

Our study encompasses several limitations. Patients were encouraged to forcefully cough twice to
 contaminate surfaces. However, we cannot exclude that potentially repeated coughing over a prolonged
 time results in a more effective virus transfer compared to our controlled conditions. Moreover, sneezing

can produce significantly more infectious droplets potentially containing infectious particles, therefore,
we cannot exclude potential transmissions via other this route. Furthermore, a selection bias cannot be
excluded, and the included patients are not demographically representative. Strengths of the present
study include the high viral load of the patients included, a standardized protocol for sample acquisition,
laboratory procedures and the inclusion of VoC.

276

## 277 Conclusion

- 278 The present study provides evidence that fomites may not be as critical in the transmission of SARS-
- 279 CoV-2 as initially suspected. However, the present study also provides evidence that infectious SARS-
- 280 CoV-2 can be found on some fomites after contamination with extensive amounts of saliva. Therefore,
- 281 common hygiene practices (e.g., coughing/sneezing into elbows, hand hygiene) should still be
- 282 considered to avoid the surface contamination and virus transfer. Face masks may further mitigate the
- risk of fomite transmission. Collectively, our findings suggest that fomites contaminated with
- 284 coughing are unlikely to be an important source of SARS-CoV-2 transmission.
- 285

286	Declarations
287	Ethics approval and consent to participate
288	The study was conducted according to the revised principles of the Declaration of Helsinki and was
289	approved by the ethics committee of the Ruhr-University Bochum (registration number 20-7065) in
290	November 2020. All patients gave written informed consent.
291	
292	Consent for publication
293	The study is published with patients consent.
294	
295	Availability of data and materials
296	The datasets used and/or analyzed during the current study are available from the corresponding author
297	on reasonable request.
298	
299	Competing Interests
300	The authors declare no competing interests.
301	
302	Funding
303	E.S was supported by the VIRus ALliance NRW (VIRAL) from Ministry of Culture and Science of the
304	State of North Rhine-Westphalia (323-8.03-151826).
305	
306	Author Contributions
307	Conceptualization, T.L.M., M.D., W.E.S., E.S., D.R.Q., S.P.
308	Methodology, T.L.M., M.D., D.R.Q., S.P.
309	Investigation, T.L.M., M.D., E.V., N.H.
310	Writing –Original Draft, S.P., Y.B.
311	Writing –Review & Editing, T.L.M., M.D., E.V., N.H., G.K., D.T., H.P.N., J.S., W.E.S., E.S., D.R.Q.,
312	S.P.
313	Visualization, T.L.M., D.T., S.P.

- 314 Resources, W.E.S., E.S., D.R.Q., S.P.
- 315 Supervision, D.R.Q., S.P.
- 316
- 317 Acknowledgements
- 318 We would like to thank all members of the Molecular and Medical Virology at the Ruhr-University
- 319 Bochum for their support and fruitful discussions. Furthermore, we are grateful for the support of the
- 320 healthcare workers at St. Josef-Hospital Bochum and appreciate all patients who volunteered to
- 321 participate in this study.

#### 322 References

- Wang CC, Prather KA, Sznitman J, et al. Airborne transmission of respiratory viruses. Science
   2021; 373.
- 325 2. Kratzel A, Steiner S, Todt D, et al. Temperature-dependent surface stability of SARS-CoV-2. J
  326 Infect 2020; 81:452–82.
- 327 3. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV328 2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382:1564–7.
- 329 4. Chin A, Chu J, Perera M, et al. Stability of SARS-CoV-2 in different environmental conditions.
  330 The Lancet Microbe 2020; 1.
- 331 5. Kampf G, Brüggemann Y, Kaba HEJ, et al. Potential sources, modes of transmission and
  332 effectiveness of prevention measures against SARS-CoV-2. J Hosp Infect 2020; 106:678–97.
- **333** 6. Centers of Disease Control and Prevention. Science Brief: SARS-CoV-2 and Surface (Fomite)
- 334 Transmission for Indoor Community Environments 2021. Available at:
   335 https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/surface-
- transmission.html.
- 337 7. Goldman E. Exaggerated risk of transmission of COVID-19 by fomites. The Lancet Infectious
  338 Diseases 2020; 20:892–3.
- 339 8. Who Headquarters. Therapeutics and COVID-19: living guideline. World Health Organization
  340 2021.
- 341 9. Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch
  342 hochpathogene Erreger. Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit
  343 COVID-19 2020.
- Wulff NH, Tzatzaris M, Young PJ. Monte Carlo simulation of the Spearman-Kaerber TCID50. J
  Clin Bioinform 2012; 2:5.
- 346 11. Toptan T, Hoehl S, Westhaus S, et al. Optimized qRT-PCR Approach for the Detection of Intra347 and Extra-Cellular SARS-CoV-2 RNAs. Int J Mol Sci 2020; 21.

- Faul F, Erdfelder E, Lang A-G, Buchner A. G\*Power 3: a flexible statistical power analysis
  program for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007;
  39:175–91.
- 351 13. O'Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging
  352 pandemic using the pangolin tool. Virus Evolution 2021; 7:veab064.
- 353 14. Robert Koch Insitut. Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19 2021.
- 354 Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/Steckbrief.html.
- 355 15. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors for Severe Disease and Efficacy
- of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and
- 357 Meta-Regression Analysis. Clinical Infectious Diseases 2020; 71:2199–206.
- 358 16. Robert Koch- Institut. Bericht zu Virusvarianten von SARS-CoV-2 in Deutschland (Stand:
  359 07.07.2021). Available at:
- 360 https://www.rki.de/DE/Content/InfAZ/N/Neuartiges\_Coronavirus/DESH/Bericht\_VOC\_2021-
- **361** 07-07.pdf?\_\_blob=publicationFile.
- 362 17. Kraay ANM, Hayashi MAL, Hernandez-Ceron N, et al. Fomite-mediated transmission as a
  363 sufficient pathway: a comparative analysis across three viral pathogens. BMC Infect Dis 2018;
  364 18:540.
- 365 18. Boone SA, Gerba CP. Significance of fomites in the spread of respiratory and enteric viral disease.
  366 Appl Environ Microbiol 2007; 73:1687–96.
- 367 19. Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol 2021;
  368 19:528–45.
- 369 20. Todt D, Meister TL, Tamele B, et al. A realistic transfer method reveals low risk of SARS-CoV370 2 transmission via contaminated euro coins and banknotes. iScience 2021; 24:102908.
- 371 21. Mikami T, Miyashita H, Yamada T, et al. Risk Factors for Mortality in Patients with COVID-19
  372 in New York City. J GEN INTERN MED 2021; 36:17–26.
- 373 22. Tram KH, Saeed S, Bradley C, et al. Deliberation, Dissent, and Distrust: Understanding distinct
- drivers of COVID-19 vaccine hesitancy in the United States. Clinical Infectious Diseases **2021**.

- 375 23. Butt AA, Nafady-Hego H, Chemaitelly H, et al. Outcomes Among Patients with Breakthrough
  376 SARS-CoV-2 Infection After Vaccination. Int J Infect Dis 2021; 110:353–8.
- 377 24. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review
  378 of Viral, Host, and Environmental Factors. Ann Intern Med 2021; 174:69–79.
- 379 25. Meister TL, Fortmann J, Todt D, et al. Comparable environmental stability and disinfection
  380 profiles of the currently circulating SARS-CoV-2 variants of concern B.1.1.7 and B.1.351. J
  381 Infect Dis 2021.
- 382 26. Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout SARS-CoV-2
  383 infection course. Science 2021; 373:eabi5273.
- 384 27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate.
  385 Ann Intern Med 2009; 150:604–12.
- 386 28. McWilliam H, Li W, Uludag M, et al. Analysis Tool Web Services from the EMBL-EBI. Nucleic
  387 Acids Research 2013; 41:W597-600.
- 388 29. Dereeper A, Guignon V, Blanc G, et al. Phylogeny.fr: robust phylogenetic analysis for the non389 specialist. Nucleic Acids Research 2008; 36:W465-9.
- 30. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics
- Analysis across Computing Platforms. Molecular Biology and Evolution **2018**; 35:1547–9.

Parameter	Unit	Normal range	Result
Participants	n	n/a	15
Age	years	n/a	70·5 (± 12·3)
Male / female (% female)	n	n/a	10/5 (33·3 %)
BMI	kg/m²		$28.8 (\pm 6.0)$
Arterial hypertension	n	n/a	10 (66.7 %)
- ACE inhibitors	n	n/a	3 (20 %)
Dyslipidemia	n	n/a	5 (33.3 %)
Diabetes mellitus	n	n/a	5 (33.3 %)
Currently smoking	n	n/a	8 (53.3 %)
Family history of CVD	n	n/a	4 (26.7 %)
Immunosuppression	n	n/a	5 (33.3 %)
Active malignancy	n	n/a	4 (26.7 %)
Chronic pulmonary disease	n	n/a	7 (46.7 %)
Chronic renal disease	n	n/a	3 (20 %)
Leucocytes	/µ1	4600-9500	6182·7 (± 3560·0)
Hemoglobin	g/dl	14.0-18.0	11·5 (± 2·6)
Thrombocytes	/µ1	150000-400000	175933·3 (± 64077·5)
D-dimers	µg/ml	<0.5	$1.3 (\pm 0.9)$
Lactate dehydrogenase	U/1	135-225	250 (± 63)
eGFR	ml/min/1,73m <sup>2</sup>	>90	63·4 (± 26·4)
Procalcitonin	ng/ml	<0.5	33·5 (± 124·9)
C-reactive protein	mg/l	<5.0	41·8 (± 38·9)
pH		7.35-7.45	$7.4 (\pm 0.1)$
Bicarbonate	mmol/l	22-26	26·1 (± 4·3)
Peripheral oxygen saturation	%	≥95	$93.4 (\pm 7.4)$
Air Temperature	°C	n/a	$5.5(\pm 5.5)$
Air humidity	%	n/a	72·8 (± 18·7)

Table 1: Baseline parameters including laboratory findings of the study group

Data are presented as n (% of total) or mean ( $\pm$  SD). Risk factors for severe COVID-19 were defined as age > 50 years, male sex, smokers, adiposity (BMI >30), Downs syndrome, history of cardiovascular diseases, chronic lung disease, chronic renal disease, psychiatric diseases, diabetes mellitus, malignant or hemic diseases or immunodeficiency [14]. eGFR was estimated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [27]. Peripheral oxygen saturation was determined on a finger, using a pulse oximeter. ACE = angiotensin converting enzyme. BMI = body mass index. CVD = cardiovascular disease. eGFR = estimated glomerular filtration rate.

Patient	<b>Initial CT values</b> (E-Gene/S-Gene/RdRP-Gene/N-Gene; VOC-Analyses*)	Deep Sequencing	Mutations identified in spike domains
P1	13/ - /17/15	B.1.389	<b>D614G</b> , T723I
P2	14/ - /16/17	B.1.1.70	D614G
P3	13/ - /14/15	B.1.1.70	D614G
P4	16/ - /17/20	B.1.1.70	D614G
P5	12/ - /13/14	B.1.221	S98F, <b>D614G</b>
P6	17/ - /18/16	B.1.177.7	A222V, <b>D614G</b>
P7	21/ - /22/19	B.1.177	A222V, <b>D614G</b> , A1020V
P8	16/ - /16/18	B.1.221	S98F, L141LF, <b>D614G</b>
P9	- /16/16/14	B.1.177	A222V, <b>D614G</b>
P10	- /12/13/13	B.1.1.153	D614G
P11	- /24/25/23; VOC B1.351*	B.1.351	H69Y, <b>D80A</b> , <b>D215G</b> , del242-244, <b>K417KT</b> , <b>E484EK</b> , <b>N501NY</b> , <b>D614G</b> , A701V
P12	- /24/23/32; VOC B1.1.7*	- #	_ #
P13	- /17/16/25; VOC B1.1.7*	B.1.1.7	del144, N501NY, A570D, D614G, P681H, A694AS, T716I, S982A, D1118H
P14	- /13/12/21; VOC B1.1.7*	B.1.1.7	del69-70, S98F, D138DH, H245Y, N501NY, A570D, D614G, P681H, A694AS, T716I, S982A, D1118DH
P15	- /21/20/29; VOC B1.1.7*	B.1.1.7	del69-70, del144, N501Y, A570D, D614G, P681H, A694AS, T716I, S982A, D1118H

Table 2: Viral load before sample acquisition using Naso Oropharyngeal swabs

Data is presented as individual data. Lineage of deep sequencing is presented according to the pangolin tool [13]. CT = cycle threshold resulting from RT-PCR performed at St. Josef-Hospital Bochum. VoC = variants of concern. \*VoC-Analyses started in the midst of the study period in February 2020 and was performed via melting curve analysis.

<sup>#</sup>no sufficient material available. **bold:** characteristic mutations associated with VOC according to RKI [16].

#### 396 Figures



397

**Figure 1: Viral Isolates analyzed in this study.** Spike domains (nt) of 14 samples (black dots) and the SARS-CoV-2 reference genome NC\_045512 (open circle) were assembled using Clustal Omega at EMBL-EBI [28]. Phylogenetic analysis was conducted with "One click" at Phylogeny.fr [29]and tree was visualized with MEGA X [30]. Scale bar indicates the number of changes per site in maximum likelihood inference (HKY85 substitution model); numbers at branches represent bootstrap values (1000 repetitions; cut-off  $\geq$  70%).

404



Figure 2: Quantification of viral loads and infectivity of patient swabs, "moisten" samples and
"cough" samples that could be successfully recovered in cell culture. VeroE6 cells were inoculated
with the patient material and monitored on a daily basis. Upon the emergence of cytopathic effects, the

410 supernatant was collected to determine viral loads by RT-qPCR (RNA copies/mL; indicated by <sup>1</sup>) and 411 viral titers by an endpoint-dilution assay (TCID<sub>50</sub>/mL, indicated by <sup>3</sup>). Additionally, RNA was isolated 412 from the cells and subjected to RT-qPCR to determine viral loads (RNA copies/50 ng total RNA, 413 indicated by <sup>2</sup>). For each patient (P1-P10), three panels were designed. The top small panel includes 414 exclusively data regarding the patient swabs, while the larger middle panel shows the data for the 415 "moisten" samples and the lower panel the data collected from the "cough" samples. For "moisten" and 416 "cough" samples viral loads and infectivity at nine different time points were determined. The color 417 indicates the amount of virus being detectable in each sample, with light grey being the lower limit of 418 detection to dark blue resulting in 10<sup>10</sup> RNA copies/mL, RNA copies/50 ng or TCID<sub>50</sub>/mL. The visible 419 CPE was rated two dimensionally, with light grey being "no visible CPE" and dark green being "visible 420 CPE".